subject area of
- Antibody Response in Immunocompromised Patients After the Administration of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Vaccine BNT162b2 or mRNA-1273: A Randomized Controlled Trial Journal Articles
- Antibody Responses 3-5 Months Post-Vaccination with mRNA-1273 or BNT163b2 in Nursing Home Residents Journal Articles
- Authors’ reply to the letters concerning the article “Effectiveness of the BNT162b2 vaccine in preventing COVID-19–associated deaths in Poland” Journal Articles
- BNT162b2 against COVID-19 in Brazil using a test-negative design: Study protocol and statistical analysis plan Journal Articles
- BNT162b2 mRNA COVID-19 against symptomatic Omicron infection following a mass vaccination campaign in southern Brazil: A prospective test-negative design study Journal Articles
- Bridging the gap: identifying factors impacting mRNA severe acute respiratory syndrome coronavirus 2 vaccine booster response in people with HIV-1 Journal Articles
- Canadian Rheumatology Association Recommendation for the Use of COVID-19 Vaccination for Patients With Autoimmune Rheumatic Diseases Journal Articles
- Comparison of three dosing intervals for the primary vaccination of the SARS-CoV-2 mRNA Vaccine (BNT162b2) on magnitude, neutralization capacity and durability of the humoral immune response in health care workers: A prospective cohort study Journal Articles
- Coronavirus disease 2019 vaccine effectiveness among a population-based cohort of people living with HIV Journal Articles
- Determinants of antibody response to severe acute respiratory syndrome coronavirus 2 mRNA vaccines in people with HIV Journal Articles
- Effectiveness of Pfizer-BioNTech COVID-19 vaccine as evidence for policy action: A rapid systematic review and meta-analysis of non-randomized studies Journal Articles
- Effectiveness of a fourth dose of covid-19 mRNA vaccine against the omicron variant among long term care residents in Ontario, Canada: test negative design study Journal Articles
- Frequency of positive anti-PF4/polyanion antibody tests after COVID-19 vaccination with ChAdOx1 nCoV-19 and BNT162b2 Journal Articles
- Heterogeneity of Vaccine-Induced Immune Thrombotic Thrombocytopenia after ChAdOx1 nCoV-19 Vaccination and Safety of Second Vaccination with BNT162b2 Journal Articles
-
Immune‐mediated necrotizing myopathy after
BNT162b2 vaccination in a patient with antibodies against receptor‐binding domain ofSARS‐CoV ‐2 and signal recognition particle Journal Articles - Interim Recommendations of the Advisory Committee on Immunization Practices for Use of Moderna and Pfizer-BioNTech COVID-19 Vaccines in Children Aged 6 Months–5 Years — United States, June 2022 Journal Articles
- Omission of alcohol skin cleansing and risk of adverse events in long-term care residents undergoing COVID-19 vaccination: A cohort study Journal Articles
- Protection from Omicron Infection in Residents of Nursing and Retirement Homes in Ontario, Canada Journal Articles
- Real-world effectiveness of original BNT162b2 mRNA COVID-19 against symptomatic Omicron infection among children 5–11 years of age in Brazil: A prospective test-negative design study Journal Articles
- The Advisory Committee on Immunization Practices’ Interim Recommendation for Use of Pfizer-BioNTech COVID-19 Vaccine in Children Aged 5–11 Years — United States, November 2021 Journal Articles
- The BNT162b2 (BioNTech/Pfizer) vaccine had 95% efficacy against COVID-19 ≥7 days after the 2nd dose Journal Articles
-
Thrombocytopenia following Pfizer and Moderna
SARS‐CoV ‐2 vaccination Journal Articles - Vaccine Effectiveness Against SARS-CoV-2 Infection and Severe Outcomes in the Maintenance Dialysis Population in Ontario, Canada Journal Articles
- Vaccine-induced immune thrombotic thrombocytopenia after COVID-19 vaccination: Description of a series of 39 cases in Brazil Journal Articles